Metabolic Syndrome
Conditions
Keywords
Postprandial hypertriglyceridemia, Metabolic syndrome, Endothelial function, Flow mediated dilatation, EndoPAT, Simvastatin, Ezetimibe
Brief summary
The purpose of this study is to investigate whether low-dose simvastatin in combination with ezetimibe in comparison to high-dose simvastatin alone, has a beneficial effect on the function of the endothelium after an oral fat load in patients with metabolic syndrome.
Detailed description
Metabolic syndrome is defined as a group of cardiovascular risk factors and is mainly driven by the epidemic of obesity. High blood lipid levels after a meal may be an important risk factor for cardiovascular disease. In this study we will investigate whether simvastatin in combination with ezetimibe vs. simvastatin alone, has a beneficial effect on the lipid levels after a meal, but more importantly, whether we can measure a difference in function of the endothelium. In a small pilot study we already found that the combination had a beneficial effect in comparison with simvastatin alone. Now we want to solidify these findings in a larger study.
Interventions
DRUGSimvastatin
6 weeks of treatment with simvastatin 80 mg
6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
Sponsors
Merck Sharp & Dohme LLC
dr.Frank L.J. Visseren
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Patient has a diagnosis of metabolic syndrome according to the modified 2005 AHA/NHLBI Scientific Statement with at least: \- Abdominal obesity defined as: \*Males: waist circumference \>102cm * Females: waist circumference \>88cm and two of the following 4 other criteria: \- Triglycerides\>150 mg/dL \- HDL Cholesterol * Males: HDL-C\<40 mg/dL * Females:HDL-C\<50 mg/dL - Blood pressure * Systolic Blood Pressure ≥130 mmHg or * Diastolic Blood Pressure ≥85 mmHg * Fasting glucose ≥ 100 mg/dL 2. Patient understands the study procedures, alternative treatments available, and risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 3. Patient is a male or female of 18-79 years of age on the day of signing informed consent. 4. Patient is a non-smoker. 5. Patient is willing to maintain a stable diet for the duration of the study. 6. Patient is a postmenopausal female who is not receiving hormone therapy (including cyclic and non-cyclical hormone replacement therapy or any estrogen antagonist/agonist). Postmenopausal status is defined as (1) no menses for ≥1 year but \<3 years and confirmed by FSH levels elevated into the postmenopausal range (as defined by the designated laboratory) or (2) no menses for at least 3 years. 7. Patient is naïve to lipid-lowering therapy. Naïve is defined as not being treated with a statin, a fibrate or ezetimibe for 3 months before Visit 1 (Week -2) 8. Patient has a baseline fasting LDL-C level of ≥ 100 mg/dL and \< 220 mg/dL, and TG level \< 400 mg/dL.
Exclusion criteria
1. Patient has a BMI \> 35. 2. Patient has hypersensitivity or intolerance to ezetimibe or simvastatin or any component of these medications, or to latex. 3. Patient routinely consumes more than 14 alcoholic drinks per week. 4. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent. 5. Patient has a smoking history \> 10 pack-years (1 pack-year = at least 20 cigarettes per day for a year) OR patient who has smoked within 3 months prior to Visit 1 (Week -2). 6. Patient has exclusionary laboratory values at Visit 1 (Week -2) as listed in the table below: liver transaminases (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]) \> 1.5 X ULN with no active liver disease Serum glucose \> 7.0 mmol/L Creatine kinase(CK)\> 2 X ULN Albumin:creatinine ratio \> 34 TSH \<0.3 mcIU/mL or \> 5.0 mcIU/mL 7. Patient has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate. 8. It is not possible to obtain a FMD measurement of sufficient quality at screening (Visit 1) 9. Patient has congestive heart failure, atherosclerotic vascular disease or acute or chronic coronary heart disease. 13\. Patient has had a partial ileal bypass, gastric bypass, gastric banding, celiac disease or other significant intestinal malabsorption. 15\. Patient has untreated and uncontrolled hypertension with systolic blood pressure \>160 mm Hg or diastolic \>100 mm Hg at Visit 1 (Week -2). (Patients with untreated hypertension and with office BP at Visit 1 and Visit 2 averaging 160/100 or less can be enrolled). Patients using blood pressure-lowering medication are excluded. 16\. Patient has estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 based on the 4-variable MDRD 17\. Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins at Visit 1 (Week -2). 18\. Patient has diabetes mellitus defined as a history of diabetes or fasting serum glucose \> 126 mg/dL. For the full
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Difference in (Postprandial-Fasting) FMD | After 6 weeks of treatment | A comparison of the postprandial minus fasting change in FMD under treatment with simvastatin 80 mg versus simvastatin 10/10 mg |
Secondary
| Measure | Time frame |
|---|---|
| Preprandial Endopat Measurement | after 6 weeks of treatment (crossover) |
| Postprandial Endopat Measurement | after 6 weeks of treatment (crossover) |
| Preprandial Endothelial Function Measured by FMD | after 6 weeks of treatment (crossover) |
Countries
Netherlands, Spain
Participant flow
Recruitment details
Between and patients were screened of which subjects were randomized in the following centers UMC Utrecht, Utrecht, the Netherlands AMC, Amsterdam, the Netherlands Vascular Research Center, Hoorn, the Netherlands Tweesteden Ziekenhuis, Waalwijk, the Netherlands Hospital Arnau de Vilanova, Lleida, Spain
Pre-assignment details
Prior to randomization subjects were given a 2 week placebo controled run-in phase to test for adequate compliance.
Participants by arm
| Arm | Count |
|---|---|
| Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg All patients were randomized to receive either Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg during this period | 100 |
| Total | 100 |
Baseline characteristics
| Characteristic | Simvastatin 80mg or Simvastatin/Ezetimibe 10/10mg |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 16 Participants |
| Age, Categorical Between 18 and 65 years | 84 Participants |
| Age Continuous | 57 years STANDARD_DEVIATION 9 |
| Region of Enrollment Netherlands | 84 participants |
| Region of Enrollment Spain | 16 participants |
| Sex: Female, Male Female | 40 Participants |
| Sex: Female, Male Male | 60 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 100 |
| serious Total, serious adverse events | 2 / 100 |
Outcome results
Primary
Treatment Difference in (Postprandial-Fasting) FMD
A comparison of the postprandial minus fasting change in FMD under treatment with simvastatin 80 mg versus simvastatin 10/10 mg
Time frame: After 6 weeks of treatment
Population: Analyses were performed in randomized patients who received ≥1 dose of study treatment and who had a post-randomization analysis measurement
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Simvastatin 80 mg | Treatment Difference in (Postprandial-Fasting) FMD | -0.34 % (change FMD) | Standard Error 0.21 |
| Simvastatin 10 mg / Ezetimibe 10 mg | Treatment Difference in (Postprandial-Fasting) FMD | -0.43 % (change FMD) | Standard Error 0.202 |
Comparison: Between treatment difference in the change in FMD from the fasting to the post-fat load state.~Null hypothesis was that combination therapy (simvastatin/ezetimibe) would protect the FMD in the post-fat load phase and would therefore be associated with a smaller drop in FMD~Power calculation was based on the results from a pilot study. To detect a 1.0% difference between treatments with a SD of 2.7% and a power of 90% (alfa 0.05, two tailed) 80 evaluable patients were needed.p-value: 0.766ANOVA
Secondary
Postprandial Endopat Measurement
Time frame: after 6 weeks of treatment (crossover)
Secondary
Preprandial Endopat Measurement
Time frame: after 6 weeks of treatment (crossover)
Secondary
Preprandial Endothelial Function Measured by FMD
Time frame: after 6 weeks of treatment (crossover)